TCGA-CQ-7069-01A-11R-2403-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- ANGIOGENESIS+0.460
- TNFA_SIGNALING_VIA_NFKB+0.450
- APICAL_JUNCTION+0.330
- HEDGEHOG_SIGNALING+0.330
- UV_RESPONSE_DN+0.330
- INFLAMMATORY_RESPONSE+0.320
- KRAS_SIGNALING_UP+0.320
- PROTEIN_SECRETION+0.300
Top 10 suppressed
- E2F_TARGETS-0.630
- MYC_TARGETS_V2-0.600
- OXIDATIVE_PHOSPHORYLATION-0.540
- MYC_TARGETS_V1-0.520
- G2M_CHECKPOINT-0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- ADIPOGENESIS-0.280
- DNA_REPAIR-0.260
- FATTY_ACID_METABOLISM-0.230
- SPERMATOGENESIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1b5aacb8-0e2e-4888-bc61-48c4aa4d4684 | — | — | 0.900 |
| 2 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.889 |
| 3 | SRR2932823 | — | — | 0.886 |
| 4 | 20030015.LumB | — | A | 0.885 |
| 5 | 22620634-aa34-4cb5-a37f-5a7b0c47cd0e | — | — | 0.877 |
| 6 | SRR8518425 | — | A | 0.873 |
| 7 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.873 |
| 8 | TCGA-44-6774-01A-21R-1858-07 | — | cohortA1 | 0.873 |
| 9 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.870 |
| 10 | TCGA-EW-A1J2-01A-21R-A13Q-07 | — | A | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.580 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |